I don't think you quite understand growth business in general based off that comment.
Revenue is 3.3m, yes 371.9 market cap but with growth businesses you aren't valuing them for the right now, you are looking forward at potential.
Product development is completed and now they are looking to monetize their product. They need to seek/gain approvals via various medical industry bodies (FDA etc) and then following this sign up customers.
A lot of cost early will go into the product development, but then even more will go into the commercialisation of the product through marketing, sales, submissions for approvals etc.
Very happy with the current report and will be looking to hold long term.
Ann: FY20 Full Year Results, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
-0.005(0.95%) |
Mkt cap ! $213.4M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 53.5¢ | 51.0¢ | $175.2K | 337.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 173020 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 162258 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |